Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.7 EUR | -1.27% | -2.50% | -8.24% |
14/03 | Hyloris Pharmaceuticals SA Provides Earnings Guidance for 2024 | CI |
14/03 | Transcript : Hyloris Pharmaceuticals SA, 2023 Earnings Call, Mar 14, 2024 |
Business Summary
Number of employees: 42
Sales per Business
EUR in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceuticals
100.0
%
| 3 | 100.0 % | 3 | 100.0 % | -4.68% |
Sales per region
EUR in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Belgium
100.0
%
| 3 | 100.0 % | 3 | 100.0 % | -4.68% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Thomas Jacobsen
FOU | Founder | 50 | 01/12/01 |
Stijn van Rompay
FOU | Founder | 48 | 01/12/01 |
Director of Finance/CFO | 53 | 23/21/23 | |
Dietmar Aichhorn
COO | Chief Operating Officer | - | 01/20/01 |
Sven Watthy
IRC | Investor Relations Contact | - | - |
General Counsel | 63 | 01/20/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Carolyn Myers
BRD | Director/Board Member | 66 | 01/20/01 |
James Gale
BRD | Director/Board Member | 74 | 01/20/01 |
Leon van Rompay
BRD | Director/Board Member | 75 | 01/20/01 |
Chris Buyse
BRD | Director/Board Member | 59 | - |
Stijn van Rompay
FOU | Founder | 48 | 01/12/01 |
Stefan Yee
CHM | Chairman | 62 | 01/19/01 |
Marc Foidart
BRD | Director/Board Member | - | 01/20/01 |
Thomas Jacobsen
FOU | Founder | 50 | 01/12/01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 28,000,374 | 12,146,562 ( 43.38 %) | 0 | 43.38 % |
Company contact information
Hyloris Pharmaceuticals SA
Boulevard Patience et Beaujonc N°3/1
4000, Liege
+32 4 346 02 07
http://www.hyloris.comSector
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-8.24% | 350M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- HYL Stock
- Company Hyloris Pharmaceuticals SA